Haleon PLC Sponsored ADR (HLN) has released an update.
Haleon PLC has announced the upsizing and pricing of Pfizer’s Global Offer, comprising the sale of over 790 million shares, including a mix of Ordinary Shares and American Depositary Shares. Pfizer, which will receive all proceeds from this offering, will see its stake in Haleon reduce from 32% to approximately 22.6% following the completion of the offer and an off-market share buyback by Haleon worth about £315 million. This buyback is part of Haleon’s broader £500 million share repurchase plan for 2024.
For further insights into HLN stock, check out TipRanks’ Stock Analysis page.
